市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Celcuity Inc. | 看涨 | 看涨 |
AIStockmoo 评分
0.0
| 分析师共识 | 1.5 |
| 内部交易活动 | -3.0 |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.00 |
|
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 13.21% |
| 机构持股比例 | 81.78% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Nea Management Company, Llc | 31 Dec 2025 | 3,535,561 |
| Perceptive Advisors Llc | 31 Dec 2025 | 3,160,200 |
| Avoro Capital Advisors Llc | 31 Dec 2025 | 3,111,111 |
| Soleus Capital Management, L.P. | 31 Dec 2025 | 1,808,258 |
| Deerfield Management Company, L.P. | 31 Dec 2025 | 1,714,000 |
| Tang Capital Management Llc | 31 Dec 2025 | 1,050,000 |
| Holocene Advisors, Lp | 31 Dec 2025 | 695,340 |
| 52周波幅 | ||
| 中 | 122.00 (6.81%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Needham | 10 Mar 2026 | 122.00 (6.81%) | 购买 | 117.10 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| BULLER RICHARD E | - | 114.14 | -3,000 | -342,420 |
| 累积净数量 | -3,000 | |||
| 累积净值 ($) | -342,420 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 114.14 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| BULLER RICHARD E | 董事 | 31 Mar 2026 | 自动卖出 (-) | 3,000 | 114.14 | 342,420 |
| BULLER RICHARD E | 董事 | 31 Mar 2026 | 执行期权 | 3,000 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合